Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimantadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 2/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.95 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimantadine SCHEMBL15532385 | 1.00 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL29908943 | 1.00 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL2982 | 1.00 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL2981 | 1.00 | SLC22A2 (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL4366035 | 0.97 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL28108817 | 0.97 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL40906 | 0.97 | MAPT (1.00) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL14973619 | 0.95 | SLC22A2 (0.90) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL3719331 | 0.91 | SLC22A2 (0.82) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 | |
| Rimantadine SCHEMBL1074987 | 0.91 | SLC22A2 (0.82) | SLC22A2SLC47A1MAPTNPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207145-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES | DDOST, DHX30, DDX5 | SLC22A2 1616/4885SLC47A1 114/4885MAPT 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.